Given the established dependence of GBM on PI3K/mTOR signaling, we treated neurosphere lines with sapanasertib (TAK-228), a dual mTOR1/2 kinase inhibitor, to determine sensitivity to pathway inhibition and antiproliferative effects. The gene discussed is MTOR; the disease is glioblastoma.